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Abstract
Background: FTY720 (fingolimod, Gilenya™) is an oral, blood-brain barrier (BBB)-passing drug approved as
immunomodulatory treatment for relapsing-remitting form of the multiple sclerosis (MS). In addition, FTY720 exerts
several effects in the central nervous system (CNS), ranging from neuroprotection to reduction of neuroinflammation.
However, the neurogenic and oligodendrogenic potential of FTY720 has been poorly investigated. In this study, we
assessed the effect of FTY720 on the production of new neurons and oligodendrocytes from neural stem/precursor
cells both in vitro and in vivo.
Methods: Neural stem cells (NSCs) derived from the young rat subventricular zone (SVZ) were exposed to FTY720
(10, 100 nM), and their differentiation into neurons and oligodendrocytes was measured using immunofluorescence
for anti-β-III tubulin or CNPase (2′,3′-cyclic nucleotide 3′-phosphodiesterase) as markers of mature neurons or
oligodendrocytes, respectively. In addition, intracerebroventricular (icv) administration of kainic acid (KA; 0.5 μg/2 μl)
in Sprague-Dawley rats was used as an in vivo model of neuronal death and inflammation. FTY720 was applied icv
(1 μg/2 μl), together with KA, plus intraperitoneally (ip; 1 mg/kg) 24 h before, and daily, until sacrifice 8 days after KA
injection. To visualize cell proliferation in the hippocampus and in white matter regions, rats were administered
5-bromo-2-deoxyuridine (BrdU) 100 mg/kg, ip injected every 2 days. Immunohistochemical analyses were performed
on rat brain slices to measure the production of new neuronal precursors (doublecortin/DCX+ cells) and new
oligodendrocytes precursors (proteoglycan/NG2+ cells).
Results: In this study, we observed that FTY720 increased postnatal NSCs differentiation into both neurons and
oligodendrocytes in vitro. In turn, in adult animals, FTY720 enhanced the percentage of BrdU+ cells coexpressing DCX
marker, both in basal (FTY720 alone) and in neurodegenerative (FTY720 + KA) conditions. However, FTY720 had only a
partial effect on proliferation and differentiation of oligodendrocyte progenitor cell (OPC) population in vivo.
Conclusions: FTY720 promotes neurogenesis and oligodendrogenesis in vitro under basal conditions. In addition, it
increases the generation of neuroblasts and oligodendrocytes after excitotoxic brain injury. This suggests that FTY720
has the potential to activate the neurogenic niche and thus favour tissue repair after lesion.
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Background
The mechanisms of adult brain repair and structural
plasticity have been the subject of intensive investigation
since the discovery of adult neural stem cell (NSC)
niches and their ability to proliferate and differentiate
into new neurons and glial cells [1, 2]. New neurons in
the adult brain are produced in discrete neurogenic
niches, primarily the subventricular zone (SVZ) and the
subgranular zone (SGZ) in the hippocampal dentate
gyrus (DG) [2, 3]. In turn, production of new oligoden-
drocytes in adulthood originates primarily from en-
dogenous oligodendrocytes progenitor cells (OPCs) that
are widely distributed throughout the CNS [4] and are
the major source of remyelinating oligodendrocytes after
demyelinating insults [5]. OPC survival/proliferation,
migration to the site of injury and differentiation into
mature oligodendrocytes are critical for successful remye-
lination and are often compromised after injury [1, 6].
Aging, as well as acute brain injury and neurodegenerative
diseases, or psychiatric disorders like depression, are asso-
ciated with a decline and/or dysfunction in neurogenesis
[2, 7]. Thus, strategies aimed to enhance and/or redirect
endogenous neurogenesis and oligodendrogenesis, e.g.
through the pharmacological manipulation of the neuro-
genic microenvironment, represent an attractive and
powerful therapeutic tool.
FTY720, a structural analogue of sphingosine, is prin-
cipally known as oral drug for multiple sclerosis [8]; its
bio-active form, FTY720-phosphate (FTY720-P) that
mimics the structure of sphingosine-1-phosphate (S1P)
and derives, in turn, from the phosphorylation by
sphingosine kinase 2, is a potent S1P receptor (S1PR)
modulator [9]. Interestingly, the ability of FTY720 to
pass BBB and to act, following in vivo phosphorylation,
through S1PRs expressed in CNS makes this drug
extremely versatile, and a number of direct effects on
neurons, microglia, oligodendrocytes and astrocytes have
been demonstrated [10]. The regenerative capacitive of
FTY720 has been observed both in vitro and in vivo.
FTY720 promotes OPC proliferation and differentiation
in vitro [11–13], and in vivo in experimental auto-
immune encephalomyelitis (EAE) mice model [14], and
increases the number of newly produced myelinating
cells in a model of local demyelination induced by lyso-
lecithin (LPC) [15] or enhances the proliferation and
migration of transplanted neural progenitor cells (NPCs)
in a model of viral-induced demyelination [16]. Also, a
certain ability of FTY720 to induce NPC differentiation
predominantly toward oligodendroglial lineage has
been observed in vitro and after transplantation in
mice brain [17].
FTY720 shows positive effects on survival, proliferation,
migration and differentiation of NSCs in vitro [18–21]. In
addition, in vivo chronic treatment with FTY720 increases
proliferation, survival and formation of new neurons in
healthy mouse hippocampus [19, 20], improving context-
ual fear memory [19] and enhanced learning and memory
ability [20]. Interestingly, FTY720 treatment enhances
adult neurogenesis in the hippocampal DG of mice
exposed to chronic unpredictable stress [22], an experi-
mental paradigm of depression, causing an enhanced pro-
duction of BDNF and resulting in antidepressant-like
effect. However, the role of FTY720 as neuro/oligogenic
agent remains not fully elucidated, especially in patho-
logical conditions. FTY720 would be good candidate to
modulate the microenvironment through the production
of neurothophic factors [23, 24] and to modulate the neu-
roinflammatory response. Moreover, S1PR signalling plays
a relevant role in the regulation of neurogenesis and cellu-
lar plasticity [25, 26].
In the present study, we investigated the effects of
FTY720 on the modulation of SVZ and SGZ neurogenic
niches, and the production of new neurons and oligoden-
drocytes following injury induced by intracerebroventricu-




diol) powder was gently provided by Novartis.
Animals
All procedures and experiments involving animals and
their care were carried out according to the guidelines of
the European Union Council (Directive 2010/63/EU)
and Spanish regulations (Real Decreto 53/2013) on ani-
mal ethics and welfare, and under the supervision and
with the approval of our internal animal ethics commit-
tee (University of the Basque Country, UPV/EHU). All
possible efforts were made to minimize animal suffering
and the number of animals used.
Neurosphere cultures and differentiation assay
NSC cultures were prepared from 4 to 7-day-old Sprague-
Dawley rat pups, as previously described [27, 28], with
slight modifications. Briefly, the SVZ was isolated and
minced with a McIlwain tissue chopper. SVZ tissue from
three to four brains was digested for 7 min at 37 °C in
5 ml of trypsin/EDTA (Sigma). Digestion was stopped by
adding an equal volume of trypsin inhibitor (Gibco) and
0.01% DNAse I (Sigma) for 5 min at room temperature.
The cell suspension was centrifuged for 10 min at ×600g
and the pellet mechanically dissociated 25 times in 3 ml
NeuroCultTM medium (STEMCELL Technologies) using
a glass Pasteur pipette and 20 times using 1 ml pipette
tips. The cells that remained in suspension were decanted
for 20 min and the single cell suspension counted using
the Neubauer method. Cells were seeded in proliferation
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medium [NeuroCultTM medium supplemented with 10%
neural stem cell factors from STEMCELL Technologies,
2 mM glutamine, penicillin/streptomycin mix, 20 ng/ml
EGF/epidermal growth factor (Promega), 10 ng/ml bFGF/
basic fibroblast growth factor (Promega), 10 ng/ml PEDF/
pigment epithelium-derived factor (Millipore)] at a density
of 104cells/cm2 and cultivated in suspension for 7 days at
37 °C, 5% CO2. EGF, bFGF and PEDF were added fresh
every 2–3 days. After 7 DIV (days in vitro), cells were ag-
gregated as neurospheres. To differentiate cultures from
neurons, floating neurospheres were then allowed to at-
tach onto poly-ornithine-coated glass coverslips in 24-well
plates in neuron differentiation medium (NeuroCult™
medium supplemented with differentiation factor 10×
(both from STEMCELL Technologies), NGF/nerve
growth factor (NGF-beta, human recombinant, #4303R-
100; Biovision) and BDNF/brain-derived neurotrophic fac-
tor (BDNF, human recombinant, #4004–50; Biovision))
and differentiated for additional 7 DIV in the presence of
FTY720 (reconstituted in dimethyl sulfoxide hydrochloric
acid (DMSO)/50 mM HCl). Alternatively, the neuro-
spheres were maintained for 3 days in oligodendrocyte dif-
ferentiation medium, composed of DMEM supplemented
with 4.5 mg/ml glucose and sodium pyruvate (Gibco),
SATO (100× stock solution: 100 μg/ml BSA, 100 μg/ml
transferrin, 16 μg/ml putrescine, 40 ng/ml thyroxine,
30 ng/ml tri-iodothryronine, 60 ng/ml progesterone, 40 ng/
ml selenium, all of from Sigma), 6.3 mg/ml N-acetyl-
cysteine (Sigma), 0.5 mg/ml insulin (Sigma), 1 μg/ml
CNTF/ciliary neurotrophic factor and 10 μg/ml NT3/
neurotrophin-3 (both from Peprotech). This step was
considered to be the pre-commitment stage before oligo-
dendrocyte differentiation. After 3 DIV, floating neuro-
spheres were allowed to attach onto poly-ornithine-coated
glass coverslips in 24-well plates in oligodendrocyte differ-
entiation medium and differentiated for 4 DIV in the pres-
ence of FTY720.
At the end of the differentiation phase, on DIV 14,
cells were fixed and immunostained for cell-specific
markers of mature neurons or oligodendrocytes. The
extent of differentiation both to neurons and to oligo-
dendrocytes was evaluated in treatment conditions and
control conditions as described below.
Immunocytochemistry and evaluation of neurospheres
differentiation
Following differentiation, cell cultures were fixed in 4%
paraformaldehyde and permeabilized with 0.05% Triton
and 5% normal goat serum in phosphate-buffered saline
(PBS). Primary antibody rabbit, anti-β-III tubulin (1:300;
Abcam, #Ab18207) and mouse anti-CNPase (1:500;
Sigma, #C5922) were incubated overnight at 4 °C and then
washed three times with 0.05% Triton in PBS. Alexa Fluor
488-conjugate secondary antibodies were incubated for
1 h in the dark at room temperature (1:500). After three
washes with 0.05% Triton in PBS, cells were stained for
10 min at room temperature with propidium iodide (PI)
to stain total nuclei, and further washed with PBS.
Fluorescence intensity was measured using a fluorescence
microplate reader equipped with appropriate excitation
and emission filters to detect the fluorescent signal from
Alexa 488 and PI. Differentiation was evaluated as a ratio
of fluorescence intensity from β-III tubulin or CNPase-
positive cells over total nuclei.
Intracerebroventricular injection of KA, FTY720 treatment
and BrdU labelling in adult rats
We used a total of 24 adult male Sprague-Dawley rats
(200–250 g). Rats were kept on a 12/12 h light/dark cycle
with constant ambient temperature and humidity. Food
and water were available ad libitum. We used unilateral
icv injection of KA as model of induced-seizure and neu-
rodegeneration. Rats (n = 6 per experimental group) were
anesthetized by ip of ketamine 80 mg/kg (Imalgene®,
Merial Laboratorios SA) and xylazine 10 mg/kg (Rompun®,
Bayer) and placed into a stereotaxic apparatus (David Kopf
Instruments). KA (0.5 μg in 2 μl in saline; Abcam), alone
or in combination with FTY720 (1 μg in 2 μl in saline),
was injected into the right lateral ventricle (right side re-
ferred thereafter as ipsilateral), at the following coordinates
from bregma: −1 mm anterioposterior, 2 mm mediolateral
and 4 mm dorsoventral [29]. Injections were carried out
over 5-min period using an infusion pump (KD Scientific),
with a constant infusion rate of 0.4 μl/min. Animals were
injected ip with vehicle (saline solution) or FTY720
(1 mg/kg) 24 h before icv injection and subsequent daily
until sacrifice 8 days after KA application (see Fig. 2a for
experimental design). For the ip injection, FTY720 was
freshly prepared every day. Control animals received
vehicle only. All animals received the thymidine analogue
5-bromo-2′-deoxyuridine (BrdU, Sigma, #B5002) as ip
injection (100 mg/kg, diluted in sterile saline) every 2 days
starting the day after icv injection, as previously used [30].
Rats were sacrificed 24 h after the last BrdU injection.
Histology
Eight days after icv injection, the animals were deeply
anesthetized with chloral hydrate 400 mg/kg (Panreac
Quimica) and transcardially perfused with 4% parafor-
maldehyde in 0.1M PBS (pH 7.4). Brains were removed
and immediately post-fixed in the same solution for 3 h.
Then, they were washed and stored at +4 °C in PBS/
Azide (0.02%) until sectioning. For all brains, series of
40-μm-thick coronal sections at the level of lateral
ventricles and dorsal hippocampus were cut on a vibra-
tome (HM 650V, Microm International) and used for
immunohistology on free-floating sections, as hereinafter
described. HCl antigen retrieval was used for BrdU
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immunostaining: before blocking step, sections were incu-
bated in 2N HCl at 37 °C for 30 min to denature DNA,
followed by two 10-min rinses in 0.1M sodium tetraborate
pH 8.5 at room temperature to neutralize HCl and then
rinsed twice with PBS. Immunoperoxidase staining was
used for identification of proliferating, BrdU-positive nu-
clei. Briefly, after quenching of endogenous peroxidase
(H2O2 0.3%) and blocking/permeabilization (4% normal
goat serum and 0.1% Triton X-100 in PBS), we incubated
the sections overnight at 4 °C with a rat anti-BrdU anti-
body (AbD Serotec, #MCA2060) diluted 1:400 in blocking
buffer. Subsequently, the primary antibody was detected
using biotinylated goat anti-rat secondary antibodies
(1:200), followed by incubation with avidin-biotin-
peroxidase complex (both from Vector Laboratories).
Peroxidase activity was visualized by incubation in
3,3′-diaminobenzidine (DAB) substrate (Roche). Finally,
the sections were mounted in gelatin-coated slides,
dehydrated through graded alcohols, cleared with xylene
and coverslipped with DPX.
To analyze the cell fate of BrdU-positive cells, we per-
formed double immunofluorescence colocalization studies
with cell-specific markers. The sections were incubated
with blocking and permeabilization solution (4% normal
goat serum, 0.1% Triton X-100 in PBS) for 1 h at room
temperature and then incubated overnight with the pri-
mary antibodies (diluted in the same solution) at 4 °C.
After washing with PBS, the sections were incubated with
Alexa Fluor 488- or 594-conjugate secondary antibodies
(molecular probes) diluted 1:400 in the blocking solution
for 1 h at room temperature. After washing with PBS, the
sections were mounted on gelatine-coated slides with
ProLong® Antifade Mountant (ThermoFisher Scientific).
In addition to anti-BrdU antibody, we used rabbit anti-
DCX (1:1000; Abcam, #Ab18723) as a marker of new neu-
rons and mouse anti-NG2 (1:500; Chemicon, #MAb5384)
as a marker of OPCs.
Negative controls in all experiments included the
omission of the primary antibodies and provided no
labelling, indicating the reliability and specificity of the
immunostaining.
Image capture and cell quantification
Immunoperoxidase staining
Two slices per animal were analyzed representing two
different levels of the dorsal hippocampus. The sections
were visualized using Zeiss Axioplan 2 bright field
microscope coupled to an Axiocam MRc5 digital camera
(Zeiss), and representative photomicrographs of ipsilat-
eral and contralateral DG region of the hippocampus
were taken under a ×10 magnification objective. Quanti-
tative analysis of BrdU-positive cells was performed
counting the immunoreactive cells along the whole SGZ
of DG in each slice under ×40 magnification objective.
BrdU-positive cells were considered to be within the
SGZ if they were within two cell body diameters on the
border between the granular cell layer (GCL) and the
hilus (see Fig. 2b) [31]. Immunoreactive cells were
counted in two slices per animals, and data were plotted
as the mean of BrdU-positive cells per section ± SEM.
Colocalization analysis
To analyze cell fate of newly, BrdU+ cells, double-
immunolabelled sections were imaged with a Fluoview
FV500 confocal laser scanning microscope (Olympus)
equipped with Fluoviewer software (Olympus). Positive
cells were counted using confocal acquired images, and
the percentage of BrdU+ cells colabelling with cell fate
markers was determined using Z-stack maximal projec-
tion of 5–10 confocal layers spaced 2.5 μm in coordin-
ation with three-dimensional orthogonal reconstruction of
confocal layers (ImageJ software, http://rsbweb.nih.gov/ij/
download.html). DCX and BrdU colocalization was deter-
mined over the total ipsilateral SGZ of DG in two slices
per animal corresponding to two different levels of the
dorsal hippocampus, and data is presented as mean posi-
tive cells per section in the case of total BrdU+ cells and as
percentage of DCX/BrdU double-positive cells on total
BrdU+ cells per section. NG2 and BrdU colocalization was
determined at the level of lateral ventricle and at the level
of the dorsal hippocampus: the measured areas selected
five fields of the corpus callosum (both at ventricle and
hippocampal levels), three fields of hilus and two fields of
fimbria of the dorsal hippocampus (see Figs. 4a and 5d).
Data are illustrated as the average of positive cells per
square millimeter (mm2) in the case of total BrdU+ cells
and percentage of NG2/BrdU double-positive cells on
total BrdU+ cells per mm2.
Statistical analysis
Data are expressed as mean ± SEM. Statistical analyses
were performed using Prism version 5.0 (GraphPad
Software, USA). Comparisons between the two groups
were analyzed using two-tailed Student’s t test. Com-
parisons among multiple groups were analyzed by one-
way or two-way analysis of variance (ANOVA), as
appropriate, followed by Bonferroni post hoc test.
p ≤ 0.05 or p ≤ 0.01 was defined as significant or highly
significant, respectively.
Results
FTY720 promotes differentiation of NSC cultures
We examined the neurogenic potential of FTY720 in
vitro, on differentiation of NSC derived from young rat
SVZ [27]. NSCs in culture proliferate and aggregate in
neurospheres with multipotent stem cells properties
which depending on local signals can differentiate into
neurons or glial cells. In Fig. 1a, a schematic diagram of
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the experimental conditions is reported (see ‘Methods’ for
further details). After a common phase where neurospheres
proliferate as suspension cultures, they were split into two
groups: neuron-oriented and oligodendrocyte-oriented dif-
ferentiation cultures that were exposed to specific mitogen
growth factors. At that stage, FTY720 was added in the
medium at different concentrations (10 and 100 nM) to
verify the ability of the drug, as compared to control condi-
tions, to promote differentiation toward a specific cellular
type. We measured the differentiation to neurons and to
oligodendrocytes using immunofluorescence for β-III
tubulin or CNPase, as markers of neurons or oligodendro-
cytes, respectively. FTY720 at either tested concentrations
significantly increased NSC differentiation both into neu-
rons (Fig. 1b–d) and oligodendrocytes (Fig. 1e–g), as com-
pared to control conditions.
Previous studies demonstrated that neurospheres in
culture express all five subtypes of S1P receptors [16], and
the treatment with FTY720 was able to activate intra-
cellular signalling cascades, indicating receptor binding
and activation [16, 19, 20]. FTY720 enhanced survival,
proliferation and migration of NSCs in vitro [18–21];
Fig. 1 FTY720 induces differentiation of neurospheres both into neurons and oligodendrocytes. a Schematic view of the protocol used for
differentiation of SVZ-derived neurospheres into neurons or oligodendrocytes. SVZ from young rats (P2–P4) was dissociated to obtain proliferating
NSCs. Cells were maintained for 7 days in vitro (DIV) in the presence of the mitogenic factors EGF, bFGF and PEDF (proliferation phase). After 7
DIV, neurospheres were differentiated into neurons up to 14 days, in the presence of NGF and BDNF or pre-committed to an oligodendrocytic
phenotype for 3 days and differentiated for up to 4 days in presence of NT3 and CNTF (differentiation phase). FTY720 was added to the cultures
during the differentiation phase at different concentrations (10 and 100 nM). At DIV 14, cells were fixed and immunofluorescence was performed using
anti-β-III tubulin (b, c) or CNPase (e, f) as markers of mature neurons or oligodendrocytes, respectively (b, c and e, f: representative photomicrographs
of the staining). Total nuclei were stained with propidium iodide (PI). Fluorescence intensity both from neurons (β-III tubulin) or oligodendrocytes
(CNPase) and total nuclei (PI) was measured using a fluorescence plate reader with appropriate excitation and emission filters. Differentiation was
evaluated as a ratio of β-III tubulin or CNPase fluorescence intensity over total nuclei fluorescence intensity (d, g). Data are expressed as mean ± SEM
of 6–7 independent experiments. Statistical analysis: paired, two-tailed Student t test; *p < 0.05 and **p < 0.01 vs control
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however, effect on differentiation remains controversial.
Our results, demonstrating a positive effect of FTY720 on
differentiation of postnatal NSCs, both to neurons and oli-
godendrocytes, indicate that FTY720 is able to accelerate
neurogenesis and oligodendrogenesis from neural precur-
sors and suggest a potential neurogenic role also in vivo.
To verify that the observed effect is due to involvement of
S1PRs pathways, we performed the same differentiation
experiment using FTY720-P instead of FTY720, obtaining
similar results (see Additional file 1: Figure S1).
FTY720 does not alter the number of proliferating cells in
SGZ after KA-induced injury in vivo
Confident with our results in vitro, we decided to ex-
plore the effect of FTY720 in adult neurogenesis in vivo,
under neurodegenerative and neuroinflammatory condi-
tions. For this aim, we investigated the effects of
FTY720 in adult rat hippocampal neurogenesis following
KA-induced acute neuronal death. All animals treated
with KA experienced seizures in the first 2–3 h after icv,
and we previously demonstrated that FTY720 reduced
CA3 excitotoxic neuronal death and microgliosis
associated with KA-induced status epilepticus [32]. We
speculated whether modulation of adult neurogenesis by
FTY720 could contribute to tissue repair in addition to
the observed neuroprotection. To test that possibility,
KA was injected in the right lateral ventricle (0.5 μg/
2 μl), alone or in combination with FTY720 (1 μg/2 μl);
in parallel, animals also received ip injection of FTY720
(1 mg/kg) or vehicle, from day −1 every day until 24 h
before sacrifice (Fig. 2a). Animals were split into a total
of four experimental groups: control (animals receiving
vehicle icv and ip), FTY720 (animals receiving FTY720
icv and ip), KA (animals receiving KA icv and vehicle ip)
and KA + FTY720 (animals receiving KA and FTY720
icv and FTY720 ip). Also, all animals were treated with
BrdU (100 mg/kg, ip), starting from post-injection day 1
and every second days until 24 h before sacrifice (Fig. 2a),
Fig. 2 KA icv injection increases cell proliferation in dentate gyrus (DG). a Scheme of in vivo experimental protocol and b schematic diagram of
the DG. Positive cells were considered to be within the SGZ if they were within two cell body diameters of the border between the GCL and the
hilus. c Quantitative analysis of the immunoperoxidase staining for BrdU in ipsilateral (ipsi) and contralateral (contra) SGZ of the dorsal hippocampus
in control, FTY720, KA and KA + FTY720-treated animals. Immunoreactive cells for BrdU were counted in two sections per rat using a bright field
microscopy and a 40× objective. Data were plotted as the mean of BrdU+ cells per slice ± SEM. Statistical analysis: one-way ANOVA followed by
Bonferroni post hoc test; **p < 0.01 vs control. Two-way ANOVA showed no significant difference between ipsilateral and contralateral BrdU+ cells in
SGZ. N = 6 for each experimental group. d Representative images of immunoperoxidase staining of BrdU in ipsilateral and contralateral DG in all
experimental groups. Scale bar: 200 μm
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to label all proliferative cells at the S phase of cell cycle.
Eight days after icv injection of KA, animals were sacri-
ficed and immunohistochemistry for BrdU performed on
40-μm-thick brain slices at the level of dorsal hippocam-
pus. The number of BrdU+ cells was counted in the SGZ
of the DG, to estimate the effect of FTY720 on the prolif-
eration of NSCs in adult rats in basal and neurodegenera-
tive conditions. Positive cells were considered to be within
SGZ if they were within two cell body diameters on the
border between the GCL and the hilus (Fig. 2b). Figure 2d
shows representative photomicrographs of BrdU staining
in ipsilateral and contralateral DG (at dorsal hippocampus
level), whereby GCL and SGZ are indicated by arrows.
Quantitative analysis of the number of BrdU+ cells in SGZ
revealed that KA induced a significantly increase in prolif-
eration both in ipsilateral and contralateral hippocampus
(Fig. 2c), as reported in previous studies [2, 31]. FTY720,
alone or in combination with KA, slightly enhanced the
number of positive cells, but the increase was not statisti-
cally significant (Fig. 2c). No significant differences were
observed between the ipsilateral and contralateral hemi-
spheres. Subsequent analyses were then performed only in
the ipsilateral hemisphere. BrdU+ cells in GCL were also
counted, but no significant differences were observed be-
tween groups (data not shown). Data obtained with BrdU
immunolabelling were further confirmed by immunohis-
tochemistry for the proliferation marker Ki67 (a nuclear
protein expressed in active dividing cells) (Additional
file 2: Figure S2).
FTY720 increases the number of new neuroblasts in SGZ
after KA-induced toxicity in vivo
To establish the nature of newborn cells in SGZ, we car-
ried out double immunofluorescence for BrdU and
DCX, a microtubule-associated protein expressed by
neuronal precursor cells and immature neurons (Fig. 3a, b)
and quantified BrdU and BrdU/DCX double-positive cells
in the ipsilateral SGZ. Consistent with the results described
above by immunohistochemistry (Fig. 2c), no difference
was observed between KA and KA + FTY720-treated
group (Fig. 3c) in terms of total BrdU+ cells, whereas
FTY720 significantly increased the percentage of BrdU
cells coexpressing DCX marker, both in basal (FTY720
alone) and in after injury (KA + FTY720) conditions
(Fig. 3d), indicating a role for this drug in promoting new
neuroblasts formation in the hippocampus. The same re-
sults were obtained when FTY720 was applied ip only, as
reported in Additional file 3: Figure S3.
FTY720 has only a partial effect on OPC pool in vivo after
KA-induced injury
FTY720 exerts direct effects on oligodendrocytic lineage
via S1P receptors modulation, promoting survival, differ-
entiation and remyelination [11, 12, 14, 33]. We tested
the hypothesis that FTY720 could enhance oligodendro-
genesis in vivo, promoting OPC proliferation and differ-
entiation into mature oligodendrocytes after a brain
injury caused by icv injection of KA, as oligodendrocytes
are also vulnerable to excitotoxic insults [34]. Thus, we
quantified newborn BrdU+ cells with an oligodendrocytic
fate using the OPC marker NG2, at two different brain
levels in order to cover a wider brain area: the ipsilateral
corpus callosum (CC), fimbria and hilus at the level of
the dorsal hippocampus and the ipsilateral CC at level of
the lateral ventricles (Fig. 4a and 5d). Figure 4 summa-
rizes the results obtained at the level of the dorsal hippo-
campus in term of total BrdU+ cells per mm2 (Fig. 4c–f ),
and percentage of NG2/BrdU double-positive cells over
total BrdU+ cells per mm2 (Fig. 4g–j), in hilus, fimbria
and CC, separately and all together. Percentage of
newborn NG2+ cells has a tendency to decrease in KA-
treated animals (significantly in the hilus, fimbria and in all
regions pool together), compared to control, whereas sig-
nificant effect between KA-treated and (KA + FTY720)-
treated group was found only in the corpus callosum and
in all regions plotted together. The number of analyzed
cells and P values resulting from all statistical analyses are
showed in Tables 1 and 2, respectively.
However, we observed no differences in the number of
newly formed NG2+ cells at the level of lateral ventricle
(Fig. 5). We also quantified in the same brain regions the
number of mature oligodendrocytes using as a marker
APC antibodies (directed against the protein adenomatous
polyposis coli), but no significant differences were found
(data not shown) between the experimental groups.
Discussion
In the present study, we provide evidence for a pro-
neurogenic effect of FTY720 in vitro, whereby this drug
favours the differentiation of postnatal SVZ-derived
NSCs into both neurons and oligodendrocytes. In turn,
in adult animals, FTY720 increases in the number of
new neuroblasts in SGZ following KA-mediated injury.
The OPC population is only partially affected by
FTY720 treatment, depending on the analyzed regions.
Postnatal and adult NSCs could have different differ-
entiation potentials, although a recent study in vitro re-
ported a similar behaviour of postnatal (p7) and adult
(p42)-derived NSCs [28]. Despite this consideration, we
decided to use adult animals for the in vivo protocol as
the main aim of our study was to examine the response
of neurogenic niches to FTY720 after injury.
KA-induced status epilepticus (SE) is an extensively used
seizure model of temporal lobe epilepsy in rodents and
results primarily in a reproducible pattern of excitotoxic
hippocampal cell death [35, 36], as well as in a robust neu-
roinflammatory response and gliosis [37, 38]. KA-induced
seizures in rodents also increase neurogenesis in DG, but
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in an aberrant and possibly pathogenic way [39]. In fact,
KA-induced neurogenesis is accompanied by immature
neurons and granule cell dispersion within the adult GCL,
widening of the hippocampal GCL, abnormal morphology
of newborn neurons and mossy fiber sprouting, abnormal
connectivity of newborn neurons into the hippocampal
circuits [2, 31, 40–43]. Increase of neurogenesis after SE is
considered predominantly detrimental, contributing to
epileptogenesis and chronic epilepsy [31], as well as to
NSCs pool depletion in SGZ [44]. On the other hand,
aging affects hippocampal neurogenic response to seizures
with a shift toward glial differentiation, and severe cogni-
tive deficits and chronic epilepsy transformation [45, 46].
Interestingly, SE-induced epileptogenesis is not disrupted
in cyclin D2 knockout mice which has a markedly reduced
adult neurogenesis [47]. Therefore, the functional rele-
vance of increased neurogenesis after seizure remains
doubtful [31, 48] though it is assumed that the neurogenic
response after acute seizure activity occurs as an endogen-
ous repair mechanism.
In this study, we observed an increase of proliferating cells
after KA-induced injury which was not modulated by
FTY720. Interestingly, FTY720 favours a neuronal fate
choice of newly born cells, as a significant number of BrdU+
cells are also DCX+. Thus, FTY720 redirects endogenous
neurogenesis to a neuronal fate which may contribute to
the previously observed improved neuronal outcome in this
injury paradigm [32]. These findings are in line with those
Fig. 3 Treatment with FTY720 increases the number of DCX-positive cells in SGZ. a, b Representative images acquired using confocal laser
scanning microscopy of double immufluorescence staining for BrdU and DCX in ipsilateral DG in saline-injected control (vehicle), FTY720, KA and
KA + FTY720 injected animals, 8 days after surgery. (i) Low magnification and (ii) Z-stack maximal projection of 5–10 confocal layers spaced by
2.5 μm of the area marked with a white frame in (i). Scale bar (i) 200 μm and (ii) 50 μm. c, d Quantitative analysis of BrdU+ and DCX+/BrdU+ cells
within the SGZ of the ipsilateral dorsal hippocampus. Positive cells were counted using confocal acquired images over the total SGZ of the ipsi
DG in two sections per animal. DCX and BrdU colocalization was determined examining three-dimensional orthogonal reconstruction of confocal
layers (ImageJ software). Data are presented as c mean of positive cells per slice ± SEM and d percentage of DCX+ cells over BrdU+ total cells. Statistical
analysis: one-way ANOVA followed by Bonferroni post hoc test; *p < 0.05, **p < 0.01. N = 6 for each experimental group. e Representative confocal
Z-stack images showing BrdU and DCX colocalization, as single and merged channels
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Fig. 4 Effect of FTY720 treatment on the number of NG2+ cells at the level of the dorsal hippocampus. a Schematic diagram of measured areas
in the ipsilateral hemisphere (dorsal hippocampus level), in hilus (H), fimbria (F) and corpus callosum (CC). b Representative Z-stack maximal projection of
immufluorescence staining for BrdU and NG2 in the (i) hilus, (ii) fimbria and (iii) corpus callosum (KA + FTY720 group). Scale bar: 50 μm. c–j Quantitative
analysis of BrdU+ and NG2+/BrdU+ cells. NG2 and BrdU colocalization was determined examining three-dimensional orthogonal reconstruction of
confocal layers (ImageJ software). Data are presented as c–f mean of positive cells per mm2 ± SEM and g–j percentage of NG2+ cells over BrdU+ total
cells per mm2. Statistical analysis: unpaired, two-tailed Student t test; *p < 0.05, **p < 0.01. N = 4 animals for each experimental group
Fig. 5 Treatment with FTY720 does not affect the number of NG2+ cells at the level of lateral ventricle. a, b Quantitative analysis of BrdU+ and
NG2+/BrdU+ cells. Positive cells were counted using confocal acquired images in the corpus callosum at the level of lateral ventricle (ipsilateral
hemisphere). NG2 and BrdU colocalization was determined examining three-dimensional orthogonal reconstruction of confocal layers (ImageJ
software). Data are presented as a mean of positive cells per mm2 ± SEM and b percentage NG2+ cells over BrdU+ total cells per mm2. Statistical
analysis: unpaired t test, two-tailed. N = 4 for each experimental group. c Representative double Z-stack maximal projection of immufluorescence
staining for BrdU and NG2 in the corpus callosum (KA + FTY720 group). Scale bar: 50 μm. d Schematic diagram of measured areas in white matter
ipsilateral hemisphere (lateral ventricle level)
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showing enhanced hippocampal neurogenesis and memory
after chronic administration with FTY720 in adult mice [19,
20] and in mice subjected to chronic unpredictable stress,
an experimental paradigm of depression [22]. However, fur-
ther analysis will be require to verify morphology, integra-
tion in GCL, and functionality of new neuroblasts in
FTY720-treated animals in our experimental conditions and
at longer time points after injury. The use of later markers
for fully mature neurons (e.g. NeuN) in combination with
BrdU staining would allow to determine whether the neuro-
genic potential of FTY720 is long-lasting and whether
DCX-positive cells can exhibit long-term survival in the
SGZ–GCL and constitute a proportion of mature granule
cells. FTY720 also reduces microgliosis and brain inflamma-
tion after KA-induced SE [32, 49]. Pro-inflammatory micro-
glia have a negative impact on neurogenesis [50, 51], thus
FTY720, modulating the inflammatory response, may exert
its proneurogenic activity modifying the microenvironmen-
tal milieu after acute injury.
Mobilization of OPC population after demyelinating
injury represents an attractive therapeutic strategy to
support remyelination and consequently brain function.
Zhang and colleagues recently demonstrated that
FTY720 promotes proliferation and differentiation of
OPCs in EAE mice model, in the SVZ, striatum, corpus
callosum, and white matter spinal cord, by activating
pathways of oligodendrogenesis [14]. OPCs and oligo-
dendrocytes are susceptible to excitotoxic damage, and
myelin degeneration has been observed at various time
points and in different brain regions after KA-induced
neuronal death [52]. Therefore, KA-induced acute injury
represents a good model to test the oligodendrogenic effect
of FTY720, and as previous studies have demonstrated how
pilocarpine-induced SE increases SVZ gliogenesis and at-
tracts newly generated glia to regions of hippocampal dam-
age [53]. Nevertheless, in our experimental conditions, after
treatment with FTY720, we found a small, though signifi-
cant, change in the number of newly generated OPC/NG2
cells in the analyzed area. Thus, in the corpus callosum at
the level of dorsal ipsilateral hippocampus, near the most
profusely damaged area, we observed a significant increase
of newly generated NG2+ cells in KA + FTY720-treated
group compared to KA-treated animals, and the effect was
maintained when we pooled together data from all analyzed
regions. However, the effect was lost at more distal white
matter regions, such as the corpus callosum at the level of
lateral ventricles. Additional studies are needed to better
understand the role of FTY720 on oligodendrogenesis in
pathological conditions, mostly at later disease stages.
Alternatively, to enhance repair by endogenous NSCs,
neuronal or oligodendrocyte lost after disease can be re-
placed by engraft of exogenous stem cells [54]. However, this
therapeutic strategy may be limited due to cell death of
transplanted cells, rejection of donor cells and tumorigenesis
[55]. In our study, we demonstrated the ability of the pro-
drug FTY720, in its non-phosphorylated form, to promote
differentiation of postnatal NSCs into both neurons and oli-
godendrocytes; therefore, FTY720 may be a promising drug
for the manipulation of NSC pool used in stem cells graft
therapies, promoting their survival, proliferation and ori-
ented differentiation, as well as integration [17, 18]. The ac-
tive form of FTY720 is considered the phosphorylated one;
however, a growing literature demonstrates the effectiveness
of the non-phosphorylated form of FTY720 not only in vivo,
where FTY720 can be phosphorylated by endogenous
sphingosine kinase 2, but also in vitro [17, 18, 20, 32,
56–58]. In our NSC cultures, we cannot exclude that the ef-
fect observed with FTY720 is due to phosphorylation
FTY720-P by sphingosine kinases eventually present in the
cultures, as reported elsewhere [17, 58]. In effect,
Table 1 Number of total analyzed cells per experimental group at
the level of dorsal hippocampus in all analyzed regions (hilus, fimbria
and corpus callosum). Number of animals per group is also reported




per groupHilus Fimbria CC
Control 75 80 165 4
FTY720 71 95 312 4
KA 205 182 124 4
KA + FTY720 185 191 280 4
Table 2 Table shows P values resulting from all statistical analyses reported in Fig. 4c-j
Student t test: P values
Hilus Fimbria CC All regions
BrdU+/mm2 % NG2+BrdU+ BrdU+/mm2 % NG2+BrdU+ BrdU+/mm2 % NG2+BrdU+ BrdU+/mm2 % NG2+BrdU+
Control vs FTY720 0.5626 0.3813 0.5164 0.4519 0.0381 0.3482 0.1145 0.8522
Control vs KA P < 0.0001 P < 0.0001 0.0031 0.0226 0.314 0.2924 0.0054 0.0032
Control vs KA + FTY720 0.0119 0.0071 0.0233 0.2703 0.0327 0.0788 0.0106 0.2051
FTY720 vs KA 0.0003 0.0066 0.0146 0.0164 0.0075 0.0633 0.1017 0.0028
FTY720 vs KA + FTY720 0.036 0.2137 0.0517 0.1463 0.9047 0.3714 0.0992 0.1637
KA vs KA + FTY720 0.2302 0.0554 0.9165 0.6478 0.0066 0.013 0.7783 0.0472
Cipriani et al. Journal of Neuroinflammation  (2017) 14:147 Page 10 of 13
experiments performed with FTY720-P are in support of
this hypothesis (Additional file 1: Figure S1), that is the effect
we showed in Fig. 1 is due to S1P receptors modulation.
Conclusions
In summary, we provided evidence of a neurogenic and
oligodendrogenic role of FTY720 in vitro, on SVZ-derived
NSCs. The efficacy of FTY720 in inducing differentiation
of NSCs was partially maintained also in vivo, as we
showed an increase in DCX expressing new neurons in
SGZ both in basal conditions and in rats after KA-
induced damage. Conversely, FTY720 had only partial ef-
fect on oligodendrogenesis in this experimental model.
These results support a modulatory effect of FTY720 on
the SVZ and SGZ neurogenic niches which in the later
may foster endogenous repair mechanisms of the adult
hippocampal region after pathological insults.
Additional files
Additional file1: Figure S1. Neurosphere culture differentiation into
neurons and oligodendrocytes. Dose-response for FTY720-P treatment
and immunofluorescence on fixed cells was performed using anti-β-III
tubulin or CNPase as markers of mature neurons or oligodendrocytes, re-
spectively, (representative photomicrographs of the staining are shown in
the upper panel of the figure). Total nuclei were stained with DAPI. Fluor-
escence intensity both from neurons (β-III tubulin) or oligodendrocytes
(CNPase), and total nuclei (DAPI) were measured using a fluorescence
plate reader with appropriate excitation and emission filters. Differenti-
ation was evaluated as a ratio of β-III tubulin or CNPase fluorescence in-
tensity over total nuclei fluorescence intensity (graphs in the lower panel
of the figure). The data are expressed as mean ± SEM of four independ-
ent experiments. Statistical analysis: two tailed Student t test; *p < 0.05
and **p < 0.01 vs control. (TIFF 4858 kb)
Additional file 2: Figure S2. Immunostaining with Ki67 showed no
relevant difference with BrdU staining. (a) Representative images of
immunoperoxidase staining of Ki67 in ipsilateral and contralateral DG in
all experimental groups. Scale bar: 200 μm. DG is surrounded in white dotted
line. GCL and SGZ are indicated with arrows. Arrowheads indicate the
magnified view in the box. (b) Quantitative analysis of the immunoperoxidase
staining for Ki67 in ipsilateral and contralateral SGZ of the dorsal hippocampus
in control, FTY720, KA and KA + FTY720-treated animals. Positive cells
were considered to be within the SGZ if they were within two cell body
diameters of the border between the GCL and the hilus. Data were plotted
as the mean of Ki67+ cells per slice ± SEM. Statistical analysis: Mann Whitney
test; *p < 0.05 vs control. Two-way ANOVA showed no significant difference
between ipsilateral and contralateral Ki67+ cells in SGZ. N = 4 for each
experimental group. (TIFF 3666 kb)
Additional file 3: Figure S3. Intraperitoneal treatment with FTY720
increases the number of new DCX-positive cells in the SGZ. Animals were
sacrificed 8 days after surgery, and 40-μm-thick coronal slices of the dorsal
hippocampus were obtained. Double immufluorescence staining for BrdU
and DCX was then performed in ipsilateral DG in vehicle (control), FTY720
(ip), KA (icv) and KA (icv) + FTY720 (ip) injected animals. BrdU and DCX-
positive cells were counted using confocal acquired images over the total
SGZ of the ipsi DG in two sections per animal, corresponding to two levels of
the dorsal hippocampus. DCX and BrdU colocalization was determined exam-
ining three-dimensional orthogonal reconstructions of confocal layers (ImageJ
software). Data are presented as (a, b) mean of positive cells per slice ± SEM
and (c) percentage of DXC+ cells over BrdU+ total cells. Statistical analysis:
one-way ANOVA followed by Bonferroni post hoc test; *p < 0.05, **p < 0.01.
The number of animals per group: control = 3, FTY720 = 3, KA = 2, KA +
FTY720 = 2. (TIFF 410 kb)
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